Safety and Efficacy Review of Doxycycline
Clinical Medicine. Therapeutics · 2009-01 · 1
DOI: 10.4137/cmt.s2035 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Medicine. Therapeutics, online erschienen am 14.05.2009. Verfasst von Natasha E. Holmes und 1 weiteren Autor:innen. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 136 Literaturangaben.
Abstract (Originalsprache)
Doxycycline is a member of the tetracycline class of antibiotics and has been used clinically for more than 40 years. It is a well-tolerated drug that is bacteriostatic and acts via the inhibition of bacterial ribosomes. It is generally given at a dose of 100-mg daily or twice daily. It is well absorbed and has generally good tissue penetration. The serum half-life is 18-22 hours and dosage does not need to be adjusted in the presence of renal or hepatic impairment. Major side effects are gastro-intestinal and dermatological and it is generally contra-indicated in pregnancy or childhood because of concerns about discolouration of developing teeth and potential effects on growing bones. Drug interactions are not common although can occur with the concomitant use of methotrexate and the oral contraceptive pill, and its absorption can be reduced by the co-administration with some antacids and iron preparations. It has activity against many organisms, including Gram-positives, Gram-negatives and atypical bacteria. In addition, it appears to have some potentially clinically useful anti-inflammatory properties.
Zitieren
APA
Holmes, N. E., & Charles, P. G. (2009). Safety and Efficacy Review of Doxycycline. Clinical Medicine. Therapeutics, 1. https://doi.org/10.4137/cmt.s2035
Vancouver
Holmes NE, Charles PG. Safety and Efficacy Review of Doxycycline. Clinical Medicine. Therapeutics. 2009;1. doi:10.4137/cmt.s2035
BibTeX
@article{Holmes2009,
author = {Holmes, Natasha E. and Charles, Patrick G.P.},
title = {Safety and Efficacy Review of Doxycycline},
journal = {Clinical Medicine. Therapeutics},
year = {2009},
volume = {1},
doi = {10.4137/cmt.s2035}
}
EUVIMED